Abstract This policy brief evaluates the potential impact of Most Favored Nation (MFN) pricing on pharmaceutical innovation and patient health. We analyze MFN pricing being imposed in Medicare and Medicaid, requiring U.S. prices for already launched drugs to match the...
Abstract Prescription drugs have drawn significant policy and public attention in discussions of rising health care costs in the United States. However, their actual contribution to the growth of total health care spending remains uncertain. Drawing on data from the...
This policy brief presents a quantitative analysis of the price of drug prescriptions filled in the United States compared to other developed nations. While past comparisons have often focused only on brand-name prescription prices, we evaluate the entire distribution...
This policy brief provides a quantitative analysis of how the Inflation Reduction Act’s (IRA) policy to set prices for select small molecule drugs 9 years after FDA approval impacts innovation and patient health. Price setting under the IRA undermines existing...
This policy brief analyzes the impact of regulatory and legislative changes within the Inflation Reduction Act (IRA) on medical R&D and patient health with respect to small molecule drugs. Initial evidence potentially suggests that the cutbacks in R&D have...
